Agios Pharmaceuticals Share Price (NASDAQ: AGIO)

$36.72

▲

0.5

(1.38%)

Live

Last updated on August 20, 2025 at 11:43 PM IST

$₹

Check the interactive Agios Pharmaceuticals Stock chart to analyse performance

Agios Pharmaceuticals stock performance

as on August 20, 2025 at 11:43 PM IST

Today's Low:$36.14
Today's High:$36.72
$36.72
1.58%
Downside
Day's Volatility :1.58%
Upside
0.0%
52 Weeks Low:$23.42
52 Weeks High:$62.58
$36.72
36.23%
Downside
52 Weeks Volatility :62.58%
Upside
41.32%

Agios Pharmaceuticals Stock Returns

Period	Agios Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	20.23%	1.5%	0.0%
6 Months	6.41%	-7.1%	0.0%
1 Year	-19.32%	-11.4%	0.0%
3 Years	42.13%	2.9%	-9.6%

Agios Pharmaceuticals, Inc. Key Stats

Check Agios Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$36.22
Open	$37.61
Today's High	$36.8
Today's Low	$36.14
Market Capitalization	$2.2B
Today's Volume	$631.6K
52 Week High	$62.58
52 Week Low	$23.415
Revenue TTM	$40.9M
EBITDA	$-456.3M
Earnings Per Share (EPS)	$11.29
PE Ratio	3.32
Profit Margin	1590.42%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	64.05%

Stock Returns calculator for Agios Pharmaceuticals Stock including INR - Dollar returns

The Agios Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Agios Pharmaceuticals investment value today

Current value as on today

₹85,725

Returns

₹14,275

(-14.27%)

Returns from Agios Pharmaceuticals Stock

₹18,164 (-18.16%)

Dollar Returns*

₹3,889 (+3.89%)

Indian investors sentiment towards Agios Pharmaceuticals Stock

25%

Period: Jul 20, 2025 to Aug 19, 2025. Change in 30 Days versus previous period

Search interest for Agios Pharmaceuticals Stock from India on INDmoney has increased by 25% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Agios Pharmaceuticals, Inc.

Name
Holdings %
Name
Holdings %
Farallon Capital Management, L.L.C.
9.81%
Vanguard Group Inc
9.78%
BlackRock Inc
8.79%
Bellevue Group AG
6.18%
State Street Corp
4.22%
T. Rowe Price Associates, Inc.
3.91%

Analyst Recommendation on Agios Pharmaceuticals Stock

Rating

Trend

Buy

73%Buy

26%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Agios Pharmaceuticals(by analysts ranked 0 to 5 stars)

Agios Pharmaceuticals Share Price Target

What analysts predicted

Upside of 29.81%

Target:

$47.67

Current:

$36.72

Agios Pharmaceuticals share price target is $47.67, a slight Upside of 29.81% compared to current price of $36.72 as per analysts' prediction.

Agios Pharmaceuticals Stock Insights

Price Movement
In the last 1 month, AGIO stock has moved down by -9.5%
Increasing Revenue
Revenue is up for the last 2 quarters, 8.72M → 12.45M (in $), with an average increase of 29.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -89.28M → -112.02M (in $), with an average decrease of 25.5% per quarter
AGIO vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 63.3% return, outperforming this stock by 82.6%
AGIO vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.3% return, outperforming this stock by 70.6%
Price to Sales
ForAGIO every $1 of sales, investors are willing to pay $50.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $24.1 for every $1 of sales.

Agios Pharmaceuticals, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$117.9M	↑ 24.92%
Net Income	$-396.6M	↑ 14.62%
Net Profit Margin	-336.36%	↑ 30.25%

	FY20	Y/Y Change
Revenue	$203.2M	↑ 72.33%
Net Income	$-335.2M	↓ 15.48%
Net Profit Margin	-164.97%	↑ 171.39%

	FY21	Y/Y Change
Revenue	$41.4K	↓ 99.98%
Net Income	$1.6B	↓ 578.71%
Net Profit Margin	3.9M%	↑ 3875445.71%

	FY22	Y/Y Change
Revenue	$14.2M	↑ 34288.66%
Net Income	$-74.6M	↓ 104.65%
Net Profit Margin	-523.56%	↓ 3875804.3%

	FY23	Y/Y Change
Revenue	$26.8M	↑ 88.36%
Net Income	$-352.1M	↑ 372.25%
Net Profit Margin	-1.3K%	↓ 789.07%

	FY24	Y/Y Change
Revenue	$36.5M	↑ 36.07%
Net Income	$673.7M	↓ 291.35%
Net Profit Margin	1.8K%	↑ 3158.55%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$8.2M	↑ 15.29%
Net Income	$-81.5M	↓ 15.0%
Net Profit Margin	-995.84%	↑ 354.86%

	Q2 FY24	Q/Q Change
Revenue	$8.6M	↑ 5.2%
Net Income	$-96.1M	↑ 17.87%
Net Profit Margin	-1.1K%	↓ 119.87%

	Q3 FY24	Q/Q Change
Revenue	$9.0M	↑ 4.05%
Net Income	$947.9M	↓ 1086.2%
Net Profit Margin	10.6K%	↑ 11690.4%

	Q4 FY24	Q/Q Change
Revenue	$10.7M	↑ 19.7%
Net Income	$-96.5M	↓ 110.18%
Net Profit Margin	-899.56%	↓ 11474.25%

	Q1 FY25	Q/Q Change
Revenue	$8.7M	↓ 18.68%
Net Income	$-89.3M	↓ 7.49%
Net Profit Margin	-1.0K%	↓ 123.69%

	Q2 FY25	Q/Q Change
Revenue	$12.5M	↑ 42.73%
Net Income	$-112.0M	↑ 25.46%
Net Profit Margin	-899.4%	↑ 123.85%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$116.6M	↑ 25.38%

	FY20	Y/Y Change
Profit	$200.4M	↑ 71.87%

	FY21	Y/Y Change
Profit	$-18.8M	↓ 109.37%

	FY22	Y/Y Change
Profit	$12.5M	↓ 166.76%

	FY23	Y/Y Change
Profit	$17.3M	↑ 38.15%

	FY24	Y/Y Change
Profit	$32.3M	↑ 86.69%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$6.2M	↑ 21.51%

	Q2 FY24	Q/Q Change
Profit	$5.5M	↓ 11.06%

	Q3 FY24	Q/Q Change
Profit	$8.2M	↑ 48.02%

	Q4 FY24	Q/Q Change
Profit	$9.5M	↑ 15.76%

	Q1 FY25	Q/Q Change
Profit	$7.6M	↓ 19.31%

	Q2 FY25	Q/Q Change
Profit	$9.5M	↑ 24.25%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-370.6M	↑ 21.75%
Investing Cash Flow	$91.4M	↓ 133.39%
Financing Cash Flow	$289.6M	↓ 46.96%

	FY20	Y/Y Change
Operating Cash Flow	$-290.8M	↓ 21.55%
Investing Cash Flow	$75.7M	↓ 17.16%
Financing Cash Flow	$261.5M	↓ 9.7%

	FY21	Y/Y Change
Operating Cash Flow	$-407.3M	↑ 40.09%
Investing Cash Flow	$1.2B	↑ 1548.64%
Financing Cash Flow	$-765.8M	↓ 392.82%

	FY22	Y/Y Change
Operating Cash Flow	$-309.5M	↓ 24.02%
Investing Cash Flow	$243.3M	↓ 80.52%
Financing Cash Flow	$2.4M	↓ 100.31%

	FY23	Y/Y Change
Operating Cash Flow	$-296.1M	↓ 4.34%
Investing Cash Flow	$239.6M	↓ 1.52%
Financing Cash Flow	$5.4M	↑ 131.19%

	FY24	Y/Y Change
Operating Cash Flow	$-389.8M	↑ 31.68%
Investing Cash Flow	$363.4M	↑ 51.7%
Financing Cash Flow	$14.4M	↑ 165.82%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-99.9M	↑ 37.77%
Investing Cash Flow	$124.6M	↑ 30.41%
Financing Cash Flow	$5.9M	↑ 592.33%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-72.6M	↓ 27.31%
Investing Cash Flow	$37.2M	↓ 70.1%
Financing Cash Flow	$1.1M	↓ 81.26%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-84.2M	↑ 16.02%
Investing Cash Flow	$250.8M	↑ 573.38%
Financing Cash Flow	$2.6M	↑ 139.95%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-133.2M	↑ 58.12%
Investing Cash Flow	$-49.2M	↓ 119.6%
Financing Cash Flow	$4.8M	↑ 83.62%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-111.5M	↓ 16.28%
Investing Cash Flow	$112.6M	↓ 329.03%
Financing Cash Flow	$1.6M	↓ 66.56%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-77.1M	↓ 30.82%
Investing Cash Flow	$79.0M	↓ 29.86%
Financing Cash Flow	$65.0K	↓ 95.99%

Agios Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Agios Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Agios Pharmaceuticals, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Agios Pharmaceuticals, Inc.	-9.32%	6.41%	-19.32%	42.13%	-8.52%
Regeneron Pharmaceuticals, Inc.	4.65%	-16.73%	-52.11%	-6.73%	-5.71%
Beone Medicines Ltd	7.16%	32.17%	61.08%	80.84%	30.07%
Vertex Pharmaceuticals Incorporated	-14.79%	-17.19%	-19.84%	32.96%	44.01%
Alnylam Pharmaceuticals, Inc.	43.03%	83.01%	63.29%	110.39%	235.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Agios Pharmaceuticals, Inc.	3.32	3.32	0.0	-7.38	0.64	-0.26	NA	23.6
Regeneron Pharmaceuticals, Inc.	14.47	14.47	1.18	39.36	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.73	27.73	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Agios Pharmaceuticals, Inc.	Buy	$2.2B	-8.52%	3.32	1590.42%
Regeneron Pharmaceuticals, Inc.	Buy	$60.8B	-5.71%	14.47	31.37%
Beone Medicines Ltd	NA	$39.3B	30.07%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.0B	44.01%	27.73	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.8B	235.62%	NA	-12.96%

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Organization	Agios Pharmaceuticals
Employees	486
CEO	Mr. Brian M. Goff M.B.A.
Industry	Health Technology

Key Management of Agios Pharmaceuticals, Inc.

Name	Title
Mr. Brian M. Goff M.B.A.	CEO & Director
Ms. Cecilia Jones	Chief Financial Officer
Mr. James William Burns	Corporate Secretary & Chief Legal Officer
Dr. Sarah Gheuens M.D., Ph.D.	Chief Medical Officer and Head of Research & Development
Ms. Tsveta Milanova	Chief Commercial Officer
Dr. Lewis clayton Cantley Ph.D.	Co-Founder
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.	Co-Founder
Dr. Craig B. Thompson M.D.	Co-Founder
Dr. Shin-San Su Ph.D.	Co-Founder
Mr. T. J. Washburn	VP, Controller & Principal Accounting Officer

Important FAQs about investing in AGIO Stock from India :

What is Agios Pharmaceuticals share price today?

Agios Pharmaceuticals share price today is $36.72 as on August 20, 2025 at 11:43 PM IST. Agios Pharmaceuticals share today touched a day high of $36.72 and a low of $36.14.

What is the 52 week high and 52 week low for Agios Pharmaceuticals share?

Agios Pharmaceuticals share touched a 52 week high of $62.58 and a 52 week low of $23.42. Agios Pharmaceuticals stock price today i.e. August 20, 2025 at 11:43 PM IST is trending at $36.72, lower by 41.32% versus the 52 week high.

How to invest in Agios Pharmaceuticals Stock (AGIO) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Agios Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Agios Pharmaceuticals Shares that will get you 0.0408 shares as per Agios Pharmaceuticals share price of $36.72 per share as on August 20, 2025 at 11:43 PM IST.

What is the minimum amount required to buy Agios Pharmaceuticals Stock (AGIO) from India?

Indian investors can start investing in Agios Pharmaceuticals (AGIO) shares with as little as ₹87.0225 or $1 (as of August 20, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹870.22 in Agios Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 20, 2025). Based on Agios Pharmaceuticals share’s latest price of $36.72 as on August 20, 2025 at 11:43 PM IST, you will get 0.2723 shares of Agios Pharmaceuticals. Learn more about fractional shares .

What are the returns that Agios Pharmaceuticals has given to Indian investors in the last 5 years?

Agios Pharmaceuticals stock has given -8.52% share price returns and 16.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?